JNJ

Johnson & Johnson's third-quarter 2026 earnings look terrible, until you dig into the story a little bit more.

Johnson & Johnson has released a string of positive trial readouts and product updates in oncology, immunology and MedTech, including data for subcutaneous amivantamab, JNJ-6143 and TREMFYA, alongside new device launches and regulatory milestones.

J&J's MedTech growth slows in Q3 amid international market challenges and Abiomed weakness.

For questions about this article or underlying research, email [email protected].

Johnson & Johnson (NYSE: JNJ) is seeing quick uptake of its oral plaque psoriasis therapy Icotyde in U.S. dermatology practices.

Key TakeawaysJohnson & Johnson stock is up 42% in the past year. Over that stretch it moved to settle its ovarian talc claims, and its newer drugs made up for Stelara’s decline.

Merck and Eli Lilly both beat Wall Street, but their paths to profit look nothing alike, and the gap between them could widen sharply as one faces a looming patent cliff and the other rides an unstoppable drug category.

According to the average brokerage recommendation (ABR), one should invest in Johnson & Johnson (JNJ). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic.

For questions about this article or underlying research, email [email protected].

Johnson & Johnson has delivered strong share gains in recent years, so the key issue now is whether the current valuation is properly backed by the cash the business is expected to generate.

Johnson & Johnson (NYSE: JNJ) reported new oncology data, including a 75% tumor response rate for JNJ-6143 in advanced prostate cancer.